Growth Metrics

Ligand Pharmaceuticals (LGND) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$4.0 million.

  • Ligand Pharmaceuticals' Income towards Parent Company rose 1735.15% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 7.38%. This contributed to the annual value of -$4.0 million for FY2024, which is 142.16% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' Income towards Parent Company stood at -$4.0 million, which was down 142.16% from -$1.7 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Income towards Parent Company ranged from a high of -$1.7 million in FY2023 and a low of -$28.1 million during FY2022.
  • In the last 3 years, Ligand Pharmaceuticals' Income towards Parent Company had a median value of -$4.0 million in 2024 and averaged -$11.3 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Income towards Parent Company soared by 94.08% in 2023, and later tumbled by 142.16% in 2024.
  • Ligand Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$9.6 million in 2020, then plummeted by 100.51% to -$19.2 million in 2021, then crashed by 46.46% to -$28.1 million in 2022, then skyrocketed by 94.08% to -$1.7 million in 2023, then crashed by 142.16% to -$4.0 million in 2024.